Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
07:45am, Thursday, 02'nd Jan 2025
INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentation Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinica
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
01:15pm, Monday, 23'rd Dec 2024
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRN
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
02:28pm, Thursday, 19'th Dec 2024
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRN
Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - December 19,
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
09:21am, Thursday, 12'th Dec 2024
Journal is the official publication of the International Union of Immunological Societies Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) i
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
07:45am, Tuesday, 10'th Dec 2024
Award is being presented during Advanced Therapies Week 2025 in Dallas Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stag
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
07:45am, Tuesday, 03'rd Dec 2024
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
07:45am, Tuesday, 19'th Nov 2024
--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnolog
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
05:47pm, Thursday, 14'th Nov 2024
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free futu
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10:00am, Thursday, 07'th Nov 2024
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotech
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
07:45am, Friday, 01'st Nov 2024
Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinica
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
08:00am, Friday, 18'th Oct 2024
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinica
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
08:00am, Wednesday, 16'th Oct 2024
PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
08:00am, Monday, 07'th Oct 2024
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals
